Back grey_arrow_rt.gif
 
Archived NATAP Articles from April 2003
 
null.gif
 
 
  1. FDA Approves New Dose Formulation of Viracept: 625 mg tablets - (5/1/03)

    2.  
  2. Liver transplants in HIV - (5/1/03)

    3.  
  3. Sperm washing in the UK: evidence of safety and efficacy - (4/30/03)

    4.  
  4. FATTY LIVER: it's affect in HIV & hepatitis - (4/30/03)

    5.  
  5. Fisting, drug use, syphilis; risk factors for hepatitis C transmission in HIV-positive gay men - (4/30/03)

    6.  
  6. Avoid Zerit, Trizivir in first-line treatment, new UK guidelines recommend: preview of British HIV Treatment Guidelines - (4/30/03)

    7.  
  7. Efavirenz more durable than nevirapine, but CNS toxicity underestimated - (4/30/03)

    8.  
  8. Invirase vs Fortovase - (4/30/03)

    9.  
  9. Baffling Resistance to SARS - (4/30/03)

    10.  
  10. Gout and HIV: another symptom of lipodystrophy - (4/30/03)

    11.  
  11. Glaxo Will Further Cut Prices of AIDS Drugs to Poor Nations - (4/30/03)

    12.  
  12. Glaxo Will Further Cut Prices of AIDS Drugs to Poor Nations - (4/29/03)

    13.  
  13. Diagnosing fibrosis in hepatitis C: Is the pendulum swinging from biopsy to blood tests? (see Editorial below by Nezam Afdahl, MD) - (4/29/03)

    14.  
  14. HIV/AIDS is Worse in the South - (4/28/03)

    15.  
  15. TRIZAL study: switching from successful HAART to TrizivirTM (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results - (4/25/03)

    16.  
  16. Does IVDU Affect HIV Progression - (4/25/03)

    17.  
  17. PDF EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B - (4/24/03)

    18.  
  18. PCP & End Stage Liver Disease are Leading Causes of Death - (4/24/03)

    19.  
  19. ADAP HIV Drug Price Negotiation - (4/24/03)

    20.  
  20. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase Ira Jacobson, MD. - (4/24/03)

    21.  
  21. "SARS Death Rate Higher Among HIV Sufferers: Montagnier" - (4/23/03)

    22.  
  22. Genotype-phenotype discordance: the evolution in our understanding HIV-1 drug resistance - (4/22/03)

    23.  
  23. Tipranavir Phase III Study Sites - Resist 1: Randomized Evaluation of Strategic Intervention in Multi-Drug Resistant Patients with Tipranavir - (4/21/03)

    24.  
  24. Key to Hepatitis Virus Persistence Found - (4/21/03)

    25.  
  25. Super-Infection with HIV - (4/21/03)

    26.  
  26. Carotid Intima-Media Thickness in Heavily Pretreated HIV-Infected Patients - (4/21/03)

    27.  
  27. High Rates of Viral Infections & HCV and For Risk Factors Among HIV-Infected and High-Risk HIV-Uninfected Women - (4/21/03)

    28.  
  28. Impaired Virologic Response to Highly Active Antiretroviral Therapy Associated With Ongoing Injection Drug Use - (4/21/03)

    29.  
  29. NEW DRUGS RESTORE IMMUNE RESPONSE BLOCKED BY HEPATITIS C VIRUS IN HUMAN CELLS - (4/21/03)

    30.  
  30. Cross-Resistance Between Amprenavir and Kaletra - (4/21/03)

    31.  
  31. Pure Protein L.L.C. Launches Hepatitis C Vaccine Discovery Project - (4/21/03)

    32.  
  32. CD4 Cell Count Continue to Increase for at Least 3 years After Starting HAART & maintaining undetectable viral load: adherence is important - (4/21/03)

    33.  
  33. "HIV Cases in Minnesota Rise in 2002" CDC HIV/STD/TB Prevention News Update - (4/17/03)

    34.  
  34. Pegylated IFN-[alpha]2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients - (4/17/03)

    35.  
  35. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy - (4/17/03)

    36.  
  36. Tenofovir-Related Nephrotoxicity in Human Immunodeficiency VirusInfected Patients: Three Cases of Renal Failure, Fanconi Syndrome, and Nephrogenic Diabetes Insipidus - (4/16/03)

    37.  
  37. Safety & Immunogenicity of Hepatitis A Vaccine in HIV-Infected Patients - (4/15/03)

    38.  
  38. IL-2 therapy and thymic production of naive CD4 T cells in HIV-infected patients with severe CD4 lymphopenia - (4/15/03)

    39.  
  39. Factors associated with the development of diabetes mellitus in HIV-infected patients on antiretroviral therapy: a case-control study - (4/15/03)

    40.  
  40. Are the recent increases in sexual risk behavior among older or younger men who have sex with men? Answer: Both - (4/15/03)

    41.  
  41. Rapid development of central adiposity after postexposure prophylaxis with antiretroviral drugs: a proof of principle? - (4/15/03)

    42.  
  42. Gaps HCV Testing & Care in VA System - (4/14/03)

    43.  
  43. Roche Receives FDA Clearance for Cobas New More Enhanced Amplicor HIV-1 Monitor Test - (4/11/03)

    44.  
  44. Press Release from Roche - Pegasys (pegylated interferon alfa-2a) Treatment for Hepatitis B - (4/11/03)

    45.  
  45. Press Release from Gilead Sciences - Hepsera Shows Sustained Liver Improvements in More Than 70 Percent of HBeAg-negative Chronic HBV Patients - (4/11/03)

    46.  
  46. Interview With Dale Kempf (Abbott Labs) Discussing Kaletra Resistance (4/9/03)

    47.  
  47. Hepatitis Updates: Lamivudine Durability in HBV Treatment; Racial Differences Regarding HCV, Iron Stores &Response to HCV Therapy; Threshold for Neutropenia in Interferon Therapy; ALT in Predicting Liver Fibrosis; RNA Interference in Discovering Drugs for HBV. - (4/9/03)

    48.  
  48. Report from The 4th International Workshop on Clinical Pharmacology of HIV Therapy - (4/7/03)

    49.  
  49. Outbreak of Hepatitis A among Men Who Have Sex with Men: Implications for Hepatitis A Vaccination Strategies - (4/7/03)

    50.  
  50. Smallpox Vaccination in 2003: Key Information, focus on HIV - (4/7/03)

    51.  
  51. Tenofovir Access Program in 68 Developing Countries - (4/7/03)

    52.  
  52. Prediction of Coronary Heart Disease Risk in HIV-Infected Patients with Fat Redistribution - (4/4/03)

    53.  
  53. NYC HIV Planning Council Investigates Ryan White Cuts Newsday (New York City) Margaret Ramirez - (4/4/03)

    54.  
  54. Hepatitis C Virus Transmission from an Antibody-Negative Organ and Tissue Donor --- United States, 2000--2002 - (4/4/03)

    55.  
  55. "AIDS Funds: More Anger; Gotbaum Blames City Agency for $14 Million Cut in Federal Aid" - (4/3/03)

    56.  
  56. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients - (4/3/03)

    57.  
  57. Durability and Success Capability of HAART: 4.5 years follow-up - (4/3/03)

    58.  
  58. Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? - (4/3/03)

    59.  
  59. New York Minority Legislative Caucus Calls on Pataki To Restore $12M in AIDS Funding to State Budget - (4/3/03)

    60.  
  60. Bayer Receives FDA Approval After Expedited Review For Hepatitis C Viral Load Assay, VERSANT HCV RNA 3.0 Assay (bDNA) - (4/3/03)

    61.  
  61. Protease Inhibitor Use and the Incidence of Diabetes Mellitus in a Large Cohort of HIV-Infected Women - (4/2/03)

    62.  
  62. Prevalence of Genotypic Drug Resistance Among a Cohort of HIV-Infected Newborns: suggesting resistance testing in newborns - (4/2/03)

    63.  
  63. Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy: in small pilot study - (4/2/03)

    64.  
  64. Drug Access State AIDS Drug Assistance Programs, NASTAD Negotiate Lower Price for Fuzeon With Roche - (4/2/03)

    65.  
  65. HIV Inhibitors: Assembly Antiviral Inhibition of the HIV-1 Capsid Protein - (4/1/03)

    66.  
  66. HIV in central and eastern Europe - (4/1/03)

    67.  
  67. HIV Genetic Variations During STI Viral Rebound - (4/1/03)

    68.